AOAC INTERNATIONAL certifies three test kits for detecting novel coronavirus on surfaces

AOAC INTERNATIONAL announced today that it has issued Certificates of Validation for three proprietary test kits that detect SARS-CoV-2, the causative agent of COVID-19 illness, on environmental surfaces. The three tests are the first to pass the rigorous independent evaluation required by the globally recognized AOAC Research Institute‘s Performance Tested MethodsSM Program, which implemented an…

Details

Invirsa obtains license from Nationwide Children’s Hospital to fight respiratory diseases

Columbus, OH – Dec. 18, 2020 – Invirsa, a Columbus-based pharmaceutical company, today announced execution of a license agreement with the Abigail Wexner Research Institute (AWRI) at Nationwide Children’s Hospital as Invirsa seeks to broaden its treatment platform to address respiratory diseases. The announcement coincides with Invirsa’s securing a $16.9 million contract from the government…

Details